Seattle Genetics Adds Marketing Boss
Seattle Genetics, the Bothell, WA-based developer of targeted antibody drugs for cancer, said today it has hired its first head of commercial operations to prepare for the introduction of what it hopes will be its first marketed product. The company (NASDAQ: SGEN) said it hired Bruce Seeley for the new position of executive vice president, commercial. Seeley will be responsible for building up the sales and marketing teams to support brentuximab vedotin, which the company expects to the U.S. market by late 2011. Seeley previously worked at Genentech as senior director for marketing of trastuzumab (Herceptin) and TDM1.